Stock Rating Upgrade
The Value Trend Rating for Emergent BioSolutions Inc (NYSE: EBS) improved of late from D to C reflecting improving fundamentals and high Appreciation Potential. Details supporting this higher rating are included in our next report.
Recent Price Action
Emergent BioSolutions Inc (NYSE: EBS) stock closed at $4.76 on 5/24/24 after a decline of -3.6%. However, trading volume in this decline was exceptionally low at 27% of normal. The stock has declined -9.7% during the last week and has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, EBS is expected to be a major Value Builder.
Emergent BioSolutions has a current Value Trend Rating of C (Neutral). This VT Rating improved in recent days from D previously. With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Emergent BioSolutions has a good Appreciation Score of 79 but a poor Power Rating of 24, resulting in the Neutral Value Trend Rating.
Be the first to comment